Kamini Raghuram1, Maram Isaac2, Junmin Yang3, Alaa AlAli4, Kamiar Mireskandari2,4, Linh G Ly5,6, Edmond Kelly3,6, Rudaina Banihani6,7, Prakesh S Shah3,6,8, Nasrin Tehrani9,10. 1. Division of Neonatology, Department of Pediatrics, University of Toronto, Toronto, ON, Canada. 2. Department of Ophthalmology and Vision Sciences, The Hospital for Sick Children, Toronto, ON, Canada. 3. Department of Pediatrics, Mount Sinai Hospital, Toronto, ON, Canada. 4. Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, ON, Canada. 5. Division of Neonatology Department of Paediatrics, The Hospital for Sick Children, Toronto, ON, Canada. 6. Department of Paediatrics, University of Toronto, Toronto, ON, Canada. 7. Department of Newborn and Developmental Paediatrics, Sunnybrook Health Sciences Centre, Toronto, ON, Canada. 8. Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada. 9. Department of Ophthalmology and Vision Sciences, The Hospital for Sick Children, Toronto, ON, Canada. Nasrin.tehrani@sickkids.ca. 10. Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, ON, Canada. Nasrin.tehrani@sickkids.ca.
Abstract
OBJECTIVE: To compare neurodevelopmental and visual outcomes in preterm infants treated with intravitreal bevacizumab (IVB) to laser ablation at 18-24 months corrected age. STUDY DESIGN: A retrospective study was performed. The primary outcome was neurodevelopmental impairment (NDI). Secondary neurodevelopmental outcomes were significant NDI (sNDI), cerebral palsy, hearing loss, and composite scores of the Bayley Scales of Infant Development, Third edition. Visual outcomes included structural and refractive outcomes. Adjusted odds ratios (AOR) were calculated controlling for GA, sex, and ROP severity and confounding baseline characteristics using a cutoff of p < 0.20. RESULTS: Thirty-four (60 eyes) infants receiving IVB and 30 (51 eyes) laser were included. No significant differences were identified in NDI (AOR 1.77, 95% CI 0.46, 6.73) or sNDI (AOR 2.31, 95% CI 0.75, 7.14). There were no other differences in outcomes. CONCLUSIONS: Larger randomized trials are required to establish long-term efficacy and safety of IVB in preterm neonates.
OBJECTIVE: To compare neurodevelopmental and visual outcomes in preterm infants treated with intravitreal bevacizumab (IVB) to laser ablation at 18-24 months corrected age. STUDY DESIGN: A retrospective study was performed. The primary outcome was neurodevelopmental impairment (NDI). Secondary neurodevelopmental outcomes were significant NDI (sNDI), cerebral palsy, hearing loss, and composite scores of the Bayley Scales of Infant Development, Third edition. Visual outcomes included structural and refractive outcomes. Adjusted odds ratios (AOR) were calculated controlling for GA, sex, and ROP severity and confounding baseline characteristics using a cutoff of p < 0.20. RESULTS: Thirty-four (60 eyes) infants receiving IVB and 30 (51 eyes) laser were included. No significant differences were identified in NDI (AOR 1.77, 95% CI 0.46, 6.73) or sNDI (AOR 2.31, 95% CI 0.75, 7.14). There were no other differences in outcomes. CONCLUSIONS: Larger randomized trials are required to establish long-term efficacy and safety of IVB in preterm neonates.
Authors: Hao Tan; Patricia Blasco; Tamorah Lewis; Susan Ostmo; Michael F Chiang; John Peter Campbell Journal: Surv Ophthalmol Date: 2021-03-02 Impact factor: 6.197